tetano
Editor, Senior Moderator
J Clin Med
. 2022 Nov 26;11(23):6999.
doi: 10.3390/jcm11236999.
Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination
Ana I Molina-Ramos[SUP] 1 2 [/SUP], Elisabeth Gómez-Moyano[SUP] 3 [/SUP], Jorge Rodríguez-Capitán[SUP] 1 2 [/SUP], María Angullo-Gómez[SUP] 1 2 [/SUP], Patricia Gallardo-Jiménez[SUP] 4 [/SUP], Iván Pérez de Pedro[SUP] 4 [/SUP], Lucía Valiente de Santis[SUP] 5 [/SUP], Beatriz Pérez-Villardón[SUP] 6 [/SUP], Isabel Piñero-Uribe[SUP] 6 [/SUP], Javier Mora-Robles[SUP] 6 [/SUP], Víctor Manuel Becerra-Muñoz[SUP] 1 2 [/SUP], Manuel Jiménez-Navarro[SUP] 1 2 [/SUP]
Affiliations
Abstract
The coronavirus disease of 2019 (COVID-19) has been a cause of significant morbidity and mortality worldwide. Among the short- and long-term consequences of COVID-19, myocarditis is a disease to be taken into consideration. Myocarditis, in general, is related to a poor prognosis. However, the epidemiology and prognosis of myocarditis related to COVID-19 are currently unknown. While vaccination against COVID-19 is of great benefit at a public health level, the risk of myocarditis should be considered in the context of the global benefits of vaccination. In this narrative review, we will summarize the etiopathogenic bases, the epidemiology, the clinical manifestations, the course, diagnosis, prognosis, and the treatment of myocarditis related to SARS-CoV-2, as well as myocarditis secondary to mRNA vaccines.
Keywords: COVID-19; mRNA vaccines; myocarditis.
. 2022 Nov 26;11(23):6999.
doi: 10.3390/jcm11236999.
Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination
Ana I Molina-Ramos[SUP] 1 2 [/SUP], Elisabeth Gómez-Moyano[SUP] 3 [/SUP], Jorge Rodríguez-Capitán[SUP] 1 2 [/SUP], María Angullo-Gómez[SUP] 1 2 [/SUP], Patricia Gallardo-Jiménez[SUP] 4 [/SUP], Iván Pérez de Pedro[SUP] 4 [/SUP], Lucía Valiente de Santis[SUP] 5 [/SUP], Beatriz Pérez-Villardón[SUP] 6 [/SUP], Isabel Piñero-Uribe[SUP] 6 [/SUP], Javier Mora-Robles[SUP] 6 [/SUP], Víctor Manuel Becerra-Muñoz[SUP] 1 2 [/SUP], Manuel Jiménez-Navarro[SUP] 1 2 [/SUP]
Affiliations
- PMID: 36498573
- DOI: 10.3390/jcm11236999
Abstract
The coronavirus disease of 2019 (COVID-19) has been a cause of significant morbidity and mortality worldwide. Among the short- and long-term consequences of COVID-19, myocarditis is a disease to be taken into consideration. Myocarditis, in general, is related to a poor prognosis. However, the epidemiology and prognosis of myocarditis related to COVID-19 are currently unknown. While vaccination against COVID-19 is of great benefit at a public health level, the risk of myocarditis should be considered in the context of the global benefits of vaccination. In this narrative review, we will summarize the etiopathogenic bases, the epidemiology, the clinical manifestations, the course, diagnosis, prognosis, and the treatment of myocarditis related to SARS-CoV-2, as well as myocarditis secondary to mRNA vaccines.
Keywords: COVID-19; mRNA vaccines; myocarditis.